Press Releases

Apr 12, 2013
Porton Down, UK, 12 April 2013: GW Pharmaceuticals plc (AIM: GWP or the “Company”) hereby provides notification that, at the General Meeting of Company held earlier today, all the resolutions set out in the Notice of General Meeting sent to shareholders on 22 March 2013 were duly passed without
Apr 03, 2013
Porton Down, UK; 3 April 2013: GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Patent and Trademark Office (USPTO) has
Mar 19, 2013
Update on Sativex® in Germany Porton Down, UK, 19 March 2013: GW Pharmaceuticals plc (AIM: GWP, “GW”), the specialty pharmaceutical company focused on cannabinoid science, today provides an update on pricing negotiations in Germany for Sativex® being conducted by GW’s licensing partner, Almirall
Feb 19, 2013
Porton Down, UK; February 19 2013: GW Pharmaceuticals plc (AIM:GWP) today announces the appointment of Cabot Brown as a non-executive director with immediate effect. Mr Brown will sit on the Nominations Committee, Audit Committee, as well as the Remuneration Committee.